Senior VP, Chief Medical Officer 

Dr. Cesare Orlandi received his M.D. with honors from the University of Pavia Medical School, Pavia, Italy.  He is licensed and board certified in cardiology in Italy, where he served as Staff Physician in the Department of Internal Medicine, Ospedale S. Matteo and University of Pavia Medical School, Pavia, Italy.  Dr. Orlandi has also held academic and hospital appointments at Harvard Medical School and Brigham and Women's Hospital in Boston, MA.  He maintains an Assistant Professor of Medicine position at Tufts University School of Medicine, in Boston, MA.  He is a Fellow of the American College of Cardiology, the European Society of Cardiology, and a member of numerous other professional societies. He has also published an extensive number of original articles, reviews, book chapters, and abstracts.

His experience in drug development spans over twenty years, ranging from early to late development and commercialization.  Over this period of time, he has been responsible for the development, submissions, and regulatory approvals of several compounds in various therapeutic areas, including cardiovascular, CNS, oncology, GI, pulmonary, infectious diseases, and others.

Prior to his current position at TransTech Pharma, Dr. Orlandi was Sr. Vice President and CMO at Cardiokine, Inc. where he led the development and the NDA filing of lixivaptan, an oral vasopressin V₂ receptor antagonist.  Previously, he served as Vice President, Global Clinical Development at Otsuka Pharmaceuticals where he was responsible –among other programs—for the development and the NDA and MAA filing of tolvaptan (Samsca®).   He has also held the Vice President, Research & Development position with Medco Research, Inc., in Research Triangle Park, NC; Ass. Medical Director and Principal Investigator, Nuclear Cardiology positions with The DuPont Merck Pharmaceutical Company in North Billerica, MA; and was a visiting scientist with the Upjohn Company in Kalamazoo, MI.